zodasiran

Sponsor Arrowhead Pharmaceuticals, INC. · listed as ARWR

READOUT Phase 3 Confidence: medium Source: clinicaltrials

zodasiran is a clinical-stage drug asset sponsored by Arrowhead Pharmaceuticals, INC., listed as ARWR. CSA tracks 1 forward catalyst for it — the nearest is a readout expected Aug 20, 2027 (day precision, medium confidence), tied to trial NCT07037771. The asset is in Phase 3 and currently recruiting, studied in Homozygous Familial Hypercholesterolemia. It appears across 2 tracked trials in the CSA sample.

Next catalyst

Event typeREADOUT

Expected date2027-08-20

As disclosedAug 20, 2027

Date precisionday

Confidencemedium

Verify at source →

Trial & sponsor

Trial (NCT)NCT07037771

PhasePHASE3

StatusRECRUITING

Lead sponsorArrowhead Pharmaceuticals

Listed asARWR

Condition(s)Homozygous Familial Hypercholesterolemia

Data, not investment advice. CSA is information, not a recommendation to buy, sell or hold any security. Estimated catalyst dates routinely slip and are graded by confidence — verify against the source link before acting.

This is one row of the free CSA sample. The full snapshot carries 2,103 forward catalysts across 139 listed sponsors.

Get the full dataset — $499 → More ARWR catalysts